Elixirgen Therapeutics key facts
as of Nov 2026- Developer of stem cell therapies designed for treating syndrome and Alzheimer's diseases through regenerative and rejuvenating medicines.
- Elixirgen Therapeutics is valued at approximately $67.0M as of Nov 2026 (last reported valuation).
- It has raised $29.1M across 8 recorded rounds; the latest was Seed Round ($4.0M) in Oct 2025.
- Notable investors include The University of Tokyo Edge Capital, Sunovion Pharmaceuticals.
- Elixirgen Therapeutics has filed 9 Form Ds with the SEC since 2018, most recently Nov 2025 ($4.0M sold to 1 investors).
- Status: Privately Held (backing).
Elixirgen Therapeutics's last reported valuation, Nov 2023. Nothing priced has surfaced since.
Elixirgen Therapeutics funding rounds
8 roundsWho backs Elixirgen Therapeutics
2Elixirgen Therapeutics valuation
Elixirgen Therapeutics's last reported valuation was $67 million in Nov 2023. No priced round, secondary trade or fund mark has surfaced since.
How much has Elixirgen Therapeutics raised?
Elixirgen Therapeutics has raised $29.1 million across 8 recorded rounds since 2018. The largest was a $7 million early-stage round in Nov 2023; the most recent was a $4 million seed round in Oct 2025.
Elixirgen Therapeutics has filed 9 Form Ds with the SEC since 2018, most recently in Nov 2025 ($4 million sold to 1 investor).
Elixirgen Therapeutics investors
2 investors are on record for Elixirgen Therapeutics, including The University of Tokyo Edge Capital and Sunovion Pharmaceuticals. The seed round in Oct 2025 drew 1 investor.
About Elixirgen Therapeutics
Developer of stem cell therapies designed for treating syndrome and Alzheimer's diseases through regenerative and rejuvenating medicines. The company's services focus on developing therapeutics from protein-based cells that utilize chromosomal features for increasing body immunity, screening DNA structures and eliminating drug-resistant bacteria and viruses, enabling medical researchers to get protein-cell-based therapies for curing chronic telomere diseases.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2012
- Employees
- 14
- Website
- elixirgentx.com/
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.